These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31877199)

  • 41. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Outcomes of Tuberculosis in Recipients After Living Donor Liver Transplantation.
    Salvador NGA; Wee SY; Lin CC; Wu CC; Lu HI; Lin TL; Lee WF; Chan YC; Lin LM; Chen CL
    Ann Transplant; 2018 Oct; 23():733-743. PubMed ID: 30337516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials.
    Hsieh CJ; Su WJ; Wu SC; Chiu JH; Lin LC
    J Adv Nurs; 2019 Mar; 75(3):640-651. PubMed ID: 30375013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India.
    Manu MS; Mehta K; Das M; Balakrishnan S; Sunil Kumar M; Rakesh PS; Sindhu MP; Valamparampil MJ; Neena PS; Satyanarayana S
    Indian J Tuberc; 2020 Apr; 67(2):216-221. PubMed ID: 32553315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
    Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
    BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
    Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
    PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    Al-Shaer MH; Mansour H; Elewa H; Salameh P; Iqbal F
    BMC Infect Dis; 2017 Feb; 17(1):118. PubMed ID: 28152986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study.
    Carvalho ACC; Amorim G; Melo MGM; Silveira AKA; Vargas PHL; Moreira ASR; Rocha MS; Souza AB; Arriaga MB; Araújo-Pereira M; Figueiredo MC; Durovni B; Lapa-E-Silva JR; Cavalcante S; Rolla VC; Sterling TR; Cordeiro-Santos M; Andrade BB; Silva EC; Kritski AL;
    Front Immunol; 2021; 12():661934. PubMed ID: 34276654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury.
    Szklo A; Mello FC; Guerra RL; Dorman SE; Muzy-de-Souza GR; Conde MB
    Int J Tuberc Lung Dis; 2007 Jul; 11(7):775-80. PubMed ID: 17609053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis.
    Laghari M; Talpur BA; Syed Sulaiman SA; Khan AH; Bhatti Z
    Int J Mycobacteriol; 2020; 9(3):281-288. PubMed ID: 32862161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
    Park JW; Curtis JR; Lee H; Lee JK; Song YW; Lee EB
    PLoS One; 2020; 15(12):e0244239. PubMed ID: 33382731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study.
    Hassen Ali A; Belachew T; Yami A; Ayen WY
    PLoS One; 2013; 8(5):e64622. PubMed ID: 23696901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
    Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
    Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.
    Yang M; Pan H; Lu L; He X; Chen H; Tao B; Liu W; Yi H; Tang S
    BMJ Open; 2019 Mar; 9(3):e027321. PubMed ID: 30928962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.